Crystal's MCW Coder Hub🧬 ICD-10-CM H35.3114 — Nonexudative AMD, Right Eye, Advanced Atrophic With Subfoveal Involvement
Billable Code Confirmed
H35.3114 is a valid, billable 7-character ICD-10-CM code for FY2025. [web:116] All seven characters are present:
H35(category) +.3(degeneration of macula) +1(nonexudative) +1(right eye) +4(advanced atrophic, WITH subfoveal involvement). No additional characters required.
Non-Billable Parent Codes — Never Submit These
- ❌
H35.311— 6-character header — missing staging character- ❌
H35.31— 5-character header — missing laterality AND staging Always submit H35.3114 (all 7 characters).
Always Assess for Vision Impairment (H54.xx) When Coding H35.3114
Subfoveal geographic atrophy is the leading cause of severe, irreversible central vision loss in the nonexudative AMD disease process. VA of 20/200 or worse — the legal blindness threshold — is common at this stage. H35.3114 without a companion H54.xx vision impairment code should be flagged for review unless the physician documents that VA is preserved despite subfoveal involvement (unusual but possible in early subfoveal extension). Legal blindness has major clinical, legal, and social consequences — its documentation in the medical record is not optional.
🔍 Code Description
ICD-10 CM H35.3114 classifies nonexudative (dry) age-related macular degeneration of the right eye at the advanced atrophic stage, with geographic atrophy (GA) involving the subfoveal center — the most severe stage of dry AMD, in which the atrophic lesion has reached and destroyed the RPE and photoreceptors at the foveal center (the anatomic point responsible for maximum visual acuity and all fine detail, reading, and facial recognition vision).1,2
When GA involves the subfoveal center, central visual acuity drops dramatically and irreversibly — typically to the 20/200 to counting fingers range, meeting the legal blindness threshold in most jurisdictions. The patient loses the ability to read standard print, recognize faces, drive, and perform most fine motor visual tasks. This represents the functional endpoint of the dry AMD disease process and the clinical situation that drives the most significant quality-of-life impact, disability documentation, and non-ophthalmologic care coordination needs (low vision rehabilitation, driving cessation counseling, ADL support referrals).2 Despite the vision loss, GA treatment (J2781/J2782) may still be appropriate to slow further peripheral GA expansion — protecting any remaining functional peripheral macula. [web:112]
🌳 Code Tree / Hierarchy
H35.3 Degeneration of Macula and Posterior Pole
│
├── H35.31 Nonexudative AMD ❌ Non-billable header
│ │
│ └── H35.311 Right Eye ❌ Non-billable header
│ │
│ ├── H35.3110 Stage unspecified ⚠️ last resort
│ ├── H35.3111 Early dry stage
│ ├── H35.3112 Intermediate dry stage
│ ├── H35.3113 Advanced, no subfoveal GA
│ └── H35.3114 ADVANCED, WITH SUBFOVEAL GA ◀ THIS CODE ✅ HIGHEST SEVERITY
H35.3114 Is the Terminal Code in the Nonexudative AMD Staging Ladder
There is no further staging code within the H35.31x family beyond H35.3114. Once subfoveal GA is documented, the dry AMD disease process has reached its clinical endpoint for the affected eye. The next code-changing event for this eye would be wet AMD conversion (H35.3211) — a distinct disease process that can occur even in eyes with advanced dry AMD — which would be coded as a separate, concurrent condition. H35.3114 and H35.3211 can co-exist in the same eye if wet AMD develops on top of existing GA.
📊 Clinical Profile — Subfoveal Geographic Atrophy
Distinguishing H35.3113 vs H35.3114 — The One Question That Changes Everything
| Question | H35.3113 | H35.3114 |
|---|---|---|
| Is GA present? | ✅ Yes | ✅ Yes |
| Is the subfoveal center involved? | ❌ NO — fovea SPARED | ✅ YES — fovea INVOLVED |
| Typical VA | 20/25-20/80 (variable) | 20/200+ — legal blindness common |
| Central scotoma? | Absent or paracentral | Present — central blind spot |
| Can patient read standard print? | Usually yes | Usually NO |
| Low vision referral indicated? | Consider if VA declining | YES — standard of care |
| Driving restriction? | Monitor — depends on VA | Almost always restricted |
| SSDI/disability documentation | Not usually | May be applicable |
| FDA-approved GA treatment? | ✅ Syfovre/Izervay | ✅ Syfovre/Izervay (continuing benefit) |
Visual Function at H35.3114 — The Complete Picture
Snellen VA Alone Understates the Functional Burden at H35.3114
Central VA (Snellen chart) captures only one dimension of visual function. At H35.3114, even patients who retain better-than-expected Snellen VA due to eccentric fixation (using a preferred retinal locus adjacent to the scotoma) may have profound functional disability:
Visual Function Domain Impact at H35.3114 Central acuity (Snellen) 20/200+ most common; eccentric fixation may preserve some Snellen VA Reading Severely impaired — magnification required; standard print impossible Facial recognition Severely impaired — classic complaint “can’t see faces” Contrast sensitivity Severely reduced Glare recovery Severely prolonged Dark adaptation Severely impaired Peripheral vision May be relatively preserved — depends on GA size Central scotoma Present — absolute — confirmed on Amsler grid and microperimetry
Eccentric Fixation — The Adaptive Mechanism of Subfoveal GA
When the foveal center is destroyed by GA, some patients unconsciously develop eccentric fixation — using a preferred retinal locus (PRL) adjacent to the central scotoma as their new “functional center.” This adaptation is the primary goal of low vision rehabilitation and allows patients with H35.3114 to:
- Read with magnification and proper lighting
- Recognize faces with training
- Maintain limited functional independence
Low vision rehabilitation should be recommended and documented at every H35.3114 encounter. The referral and the patient’s response to rehabilitation are clinically documentable and support E/M level selection when counseling time is significant.
✅ Includes
The following clinical terms map to H35.3114 — right eye, advanced atrophic, with subfoveal involvement:1
- Nonexudative AMD, right eye, advanced atrophic — geographic atrophy involving the subfoveal center
- Subfoveal geographic atrophy, right eye
- Central geographic atrophy, right eye (foveal center involved)
- Advanced dry AMD, right eye — central vision loss due to GA at foveal center
- Geographic atrophy with central scotoma, right eye
Do NOT Include Wet AMD Here
If GA is documented alongside choroidal neovascularization (CNV) in the same eye, both conditions may be present simultaneously — GA and wet AMD can co-exist. In that scenario:
These are separately codeable as concurrent conditions in the same eye. Do NOT collapse both into H35.3114 alone, and do NOT use H35.3114 to represent wet AMD. They are distinct pathologic processes with distinct treatment regimens.
❌ Excludes
Excludes 21
| Code Range | Description | Action |
|---|---|---|
| E08.311-E08.359 | Drug/chemical-induced DM with diabetic retinopathy | Diabetic retinopathy code when DM is etiology |
| E10.311-E10.359 | Type 1 DM with diabetic retinopathy | Diabetic retinopathy code when DM is etiology |
| E11.311-E11.359 | Type 2 DM with diabetic retinopathy | Diabetic retinopathy code when DM is etiology |
| E13.311-E13.359 | Other specified DM with diabetic retinopathy | Diabetic retinopathy code when DM is etiology |
👁️ Vision Impairment Coding — Critical Companion to H35.3114
This section is more expanded than in prior AMD notes because vision impairment co-coding is almost always applicable at the H35.3114 stage and is one of the most commonly missed coding opportunities in advanced dry AMD.
WHO / ICD-10 Visual Impairment Classification
| Category | VA (Better Eye, Best Correction) | ICD-10-CM Code | Right Eye |
|---|---|---|---|
| Normal vision | 20/20-20/40 | N/A | — |
| Mild visual impairment | 20/40-20/60 | H54.10 / H54.11x | H54.10 or H54.11x by eye |
| Moderate low vision (Cat 1) | 20/70-20/160 | H54.2x1 | H54.2121 (right eye Cat 1, left normal) |
| Severe low vision (Cat 2) | 20/200-20/400 | H54.2x2 | H54.2221 (right eye Cat 2, left normal) |
| Profound low vision (Cat 3) | 20/500-20/1000 | H54.2x3 | H54.2321 |
| Near-total vision loss (Cat 4) | LP to <20/1000 | H54.2x4 | H54.2421 |
| Total blindness (Cat 5) | NLP | H54.2x5 | H54.2521 |
| Legal blindness (USA) | ≤20/200 best eye OR VF ≤20° | H54.8 | Assign along with specific H54.xx |
H35.3114 + H54.xx — Always Code Both When VA Criteria Are Met
VA of 20/200 or worse is the most common finding at H35.3114 when bilateral AMD is documented. When the right eye meets low vision or legal blindness criteria — even if the left eye preserves functional acuity — the right eye-specific H54.xx codes apply independently of the better eye’s VA. Code VA impairment for each eye separately and in combination as documentation supports.
Legal Blindness — U.S. Definition and Documentation
| Legal Blindness Criterion | Threshold | Documentation Needed |
|---|---|---|
| Central VA (better eye, best correction) | ≤20/200 (6/60) | Snellen or equivalent VA test result |
| Visual field (better eye) | ≤20° diameter in best meridian | Humphrey VF or equivalent |
| Combined | Either criterion | Either finding triggers legal blindness |
Document the Legal Blindness Determination Explicitly
When a patient with H35.3114 meets legal blindness criteria, the physician should explicitly state “legal blindness” or “meets criteria for legal blindness” in the clinical note — not just report the VA number. While coding guidelines allow the coder to assign H54.8 based on documented VA that meets the threshold, explicit physician documentation of the legal blindness determination is:
- Required for DMV-related disability certifications
- Required for Social Security disability applications
- Required for low-vision device prescription justification
- Cleaner for payer medical record requests
💰 HCC Risk Adjustment (CMS-HCC v28)
| Field | Detail |
|---|---|
| CMS-HCC Model Version | v28 (2024-2025 Implementation) |
| HCC Assignment | ❌ Not Mapped |
| HCC Category | N/A |
| RAF Coefficient | 0.000 |
H35.3114 carries no direct HCC weight.
This Is the Highest-Severity AMD Code — Comorbidity Capture Is Paramount
H35.3114 patients are among the most vulnerable Medicare beneficiaries — they are elderly, visually disabled, and at high risk for falls, depression, and social isolation secondary to vision loss. At every H35.3114 encounter, ensure complete coding of:
Comorbidity Code Reason to Capture Depression (AMD-related) F32.9 or F33.x 30-40% of severe vision loss patients develop clinical depression — document and code Fall risk / history of falls Z91.81 + Z87.39x Vision loss is a major fall risk factor; capture for quality metrics Type 2 DM E11.x HCC 18 — common comorbidity CAD, heart failure I25.x, I50.x HCC 85 — common in this age group Social isolation Z60.4 Documented by physician — clinically relevant Driving cessation Z73.82 Document when physician documents driving cessation counseling
🏥 MS-DRG Assignment
MDC 02 — Diseases and Disorders of the Eye
| DRG | Title | Est. Relative Weight* |
|---|---|---|
| DRG 124 | Other Disorders of the Eye with MCC | ~0.95-1.15 |
| DRG 125 | Other Disorders of the Eye with CC | ~0.70-0.90 |
| DRG 126 | Other Disorders of the Eye without CC/MCC | ~0.50-0.70 |
*Verify against IPPS FY2025 Final Rule tables.
H35.3114 in the Inpatient Setting — Most Common Scenario Is a Fall
Patients with H35.3114 and legal blindness are at dramatically elevated fall risk. The most common inpatient scenario where H35.3114 appears is an admission for hip fracture, subdural hematoma, or other fall-related injury — where the pre-existing legal blindness from advanced AMD is a critical contributing factor that must be documented and coded. In those encounters, H35.3114 + H54.8 (legal blindness) together paint a complete picture of why the fall occurred, which supports the clinical narrative and may influence care planning, discharge disposition, and liability documentation.
🔗 Related ICD-10-CM Codes
Complete Nonexudative AMD Staging Reference — Right Eye
| Code | Stage | GA? | Subfoveal? | AREDS2? | GA Rx? | Typical VA |
|---|---|---|---|---|---|---|
| H35.3110 | Unspecified ⚠️ | ? | ? | ? | ? | Unknown |
| H35.3111 | Early | ❌ | N/A | ❌ | ❌ | 20/20-20/40 |
| H35.3112 | Intermediate | ❌ | N/A | ✅ | ❌ | 20/25-20/80 |
| H35.3113 | Advanced, no subfoveal | ✅ | ❌ Spared | ✅ | ✅ | 20/25-20/80+ |
| H35.3114 | Advanced, subfoveal | ✅ | ✅ INVOLVED | ✅ | ✅ | 20/200+ |
Critical Concurrent Conditions (continued)
| Code | Description | Relationship to H35.3114 |
|---|---|---|
| H54.8 | Legal blindness, as defined in USA | Most common — assign when VA ≤20/200 or VF ≤20° in better eye |
| H54.2x2 | Low vision, category 2 (severe) | VA 20/200-20/400 in right eye with better-seeing fellow eye |
| H54.2x1 | Low vision, category 1 (moderate) | VA 20/70-20/160 right eye — early subfoveal GA with relative preservation |
| H54.11x | Blindness, right eye, normal vision left | VA ≤20/200 right eye; left eye VA ≥20/400 — right-specific blindness |
| H54.3 | Unqualified visual loss, both eyes | When detailed VA documentation is unavailable for classification |
| H35.3211 | Exudative AMD, right eye, active CNV | Co-occurring wet AMD in same eye — both codes assignable concurrently |
| H35.3124 | Nonexudative AMD, left eye, advanced with subfoveal | Bilateral subfoveal GA — consider H35.3134 bilateral code instead |
| H35.3134 | Nonexudative AMD, bilateral, advanced with subfoveal | Both eyes confirmed subfoveal GA — bilateral code preferred |
| F32.9 | Major depressive disorder, unspecified | Vision loss-related depression — 30-40% prevalence at this stage; document and code |
| Z91.81 | History of falling | Fall risk — legal blindness dramatically elevates fall risk |
| Z73.82 | Driving status — not currently driving | When physician documents driving cessation secondary to vision loss |
| Z82.1 | Family history of blindness and visual loss | Risk factor documentation |
Bilateral Code Navigation — Advanced Subfoveal Stage
| Situation | Code Assignment |
|---|---|
| Both eyes have GA WITH subfoveal involvement, same severity | H35.3134 — bilateral, advanced atrophic with subfoveal |
| Right eye subfoveal (H35.3114) + left eye no subfoveal (H35.3123) | Separate codes — stages differ; bilateral code not appropriate |
| Right eye subfoveal (H35.3114) + left eye intermediate (H35.3122) | Separate codes — asymmetric; bilateral code not appropriate |
| Right eye subfoveal (H35.3114) + left eye wet AMD (H35.3221) | Separate codes — different disease type in left eye |
🛠️ CPT / HCPCS Codes — H35.3114 Encounters
GA Treatment — Same J-Codes as H35.3113, Same Billing Rules
| Code | Description | Application | Units |
|---|---|---|---|
| 67028-RT | Intravitreal injection, right eye | Required CPT for every Syfovre or Izervay injection — bill with drug J-code | N/A |
| J2781 | Pegcetacoplan (Syfovre) injection | 15mg dose — permanent HCPCS J-code (eff. Oct 1, 2023) [web:115] | 15 units |
| J2782 | Avacincaptad pegol (Izervay) injection | 2mg dose — permanent HCPCS J-code (eff. April 1, 2024) [web:120] | 20 units |
| 92134 | OCT posterior segment | GA lesion measurement, remaining RPE integrity, safety check at every injection visit | Each visit |
| 92250 | Fundus photography / FAF | GA boundary documentation, subfoveal status confirmation, longitudinal progression comparison | Every 3-6 months |
| 92014 | Comprehensive ophthalmological exam, established | Monitoring or injection visit exam component | Each visit |
| 92235 | Fluorescein angiography | CNV exclusion — wet AMD conversion surveillance is ongoing even at H35.3114 | As clinically indicated |
| 92083 | Visual field examination | Central scotoma delineation; paracentral field mapping; legal blindness VF documentation | As clinically indicated |
Continuing GA Treatment at H35.3114 — Clinical and Billing Justification
A common clinical misconception is that once subfoveal GA is established, GA treatments (Syfovre/Izervay) are no longer worthwhile because central vision is already lost. However, both drugs are FDA-indicated for H35.3114 without subfoveal exclusion. The clinical rationale: even after subfoveal involvement, further GA expansion continues — destroying additional macular area, further reducing any remaining VA, and eliminating functional peripheral macula. [web:112] Slowing that ongoing expansion preserves residual visual function. When billing GA treatments for H35.3114, document this rationale explicitly in the medical record to support payer prior authorization and medical necessity review. Some payers have attempted to limit GA drug coverage to subfoveal-sparing stages only — this is not consistent with FDA labeling and must be appealed with clinical evidence when denied.
Low Vision Rehabilitation Services — H35.3114 Specific
Low Vision Rehab — Underbilled and Underdocumented at H35.3114
Low vision rehabilitation is standard of care for patients with legal blindness from subfoveal GA, yet it is consistently underbilled and underdocumented in the AMD population. The following CPT codes cover low vision evaluation and rehabilitation services that may be applicable:
| CPT Code | Description | Application |
|---|---|---|
| 92065 | Orthoptic and/or pleoptic training | Eccentric viewing training — preferred retinal locus (PRL) development |
| 97535-GO | Self-care/home management training | Low vision ADL training — occupational therapy |
| 97166-GP | Occupational therapy evaluation, high complexity | Initial low vision rehab OT evaluation |
| V2600-V2615 | Low vision aids (spectacles, optical devices) | HCPCS for low vision device prescriptions |
Low Vision Rehab Referral — Document It Every Time
Whether or not the patient accepts low vision rehabilitation, the referral and discussion must be documented at every H35.3114 encounter. This documentation:
- Supports quality measure compliance (visual impairment patient counseling)
- Creates a record that the clinical team addressed the functional consequences of legal blindness
- Provides the basis for low vision device and OT service coding if the patient engages in rehabilitation
- Is legally relevant if a patient subsequently has a vision-related injury (e.g., fall, driving accident)
💊 Coding Scenarios
Scenario 1 — New Subfoveal GA Diagnosis — H35.3113 Upgrades to H35.3114 (Outpatient)
Clinical Vignette: A 81-year-old male has been on monthly Izervay injections for geographic atrophy, right eye without subfoveal involvement (H35.3113) for 8 months. At today’s monthly injection visit, OCT and FAF confirm geographic atrophy has now extended to the subfoveal center, right eye. VA: 20/250 OD (decreased from 20/50 six weeks ago), 20/30 OS. Physician documents: “GA with new subfoveal involvement, right eye — VA 20/250 — legal blindness right eye — continue Izervay, low vision rehabilitation referral placed.”
CPT / HCPCS:
- 67028-RT — Intravitreal injection, right eye
- J2782 × 20 units — Avacincaptad pegol 2mg (Izervay — 20 units)
- 92134 — OCT posterior segment (subfoveal involvement confirmation)
- 92250 — Fundus photography with FAF (GA lesion re-delineation; subfoveal boundary documentation)
- 92014 — Comprehensive ophthalmological exam, established patient (extended — VA decline, legal blindness discussion, low vision referral)
ICD-10-CM:
- H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement (upgraded from H35.3113 — GA at foveal center confirmed today)
- H54.11x — Blindness, right eye, normal vision left eye (VA 20/250 OD meets blindness criteria; OS 20/30 = normal for laterality-specific code)
- H54.8 — Legal blindness, as defined in USA (physician explicitly documents legal blindness — assign H54.8 alongside laterality-specific code)
- H35.3122 — Nonexudative AMD, left eye, intermediate dry stage (left eye unchanged — asymmetric stages; separate codes correct)
Two Vision Impairment Codes — H54.11x AND H54.8
When the physician explicitly documents legal blindness AND the right eye VA meets blindness criteria, assign both the laterality-specific blindness code (H54.11x) AND the legal blindness code (H54.8). They serve different documentation purposes — H54.11x captures the right eye-specific functional status; H54.8 captures the legal determination that triggers disability, DMV, and rehabilitation documentation pathways. These are not duplicate codes — they are complementary.
Scenario 2 — Established H35.3114 — Monthly Izervay Injection Visit, Stable (Outpatient)
Clinical Vignette: A 78-year-old female with established bilateral advanced dry AMD — right eye with subfoveal GA (H35.3114), left eye intermediate (H35.3122) — presents for her monthly Izervay injection, right eye. OCT: stable GA, no new progression since last month. No CNV. No endophthalmitis. Injection administered without complication.
CPT / HCPCS:
- 67028-RT — Intravitreal injection, right eye
- J2782 × 20 units — Avacincaptad pegol 2mg (20 units — verify every claim)
- 92134 — OCT posterior segment (stability check; safety monitoring)
ICD-10-CM:
- H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement
- H54.8 — Legal blindness (established — recode at each encounter when physician documents active legal blindness)
Recode Vision Impairment at Every Encounter — It Does Not Auto-Carry
In the outpatient setting, diagnoses must be re-coded at each encounter when they remain active and documented. H54.8 (legal blindness) does not automatically carry forward — it must be supported by current-encounter documentation of the VA finding or an explicit physician statement that the legal blindness remains present. A physician impression that lists “AMD, right eye — legal blindness — continue Izervay” is sufficient documentation to recode H54.8 at that encounter. If only “AMD” appears without the legal blindness notation, query or use VA documentation from the encounter note.
Scenario 3 — H35.3114 + Concurrent Wet AMD Conversion — Co-Existing Codes (Outpatient)
Clinical Vignette: A 84-year-old female with long-standing subfoveal GA (H35.3114), right eye presents with sudden increased visual distortion right eye. OCT reveals new subretinal fluid and CNV in the right eye, in a perifoveal location adjacent to the existing GA lesion. Physician documents: “CNV with subretinal fluid, right eye — new wet AMD conversion on background of advanced dry AMD with subfoveal GA — initiating anti-VEGF (Eylea); Izervay on hold pending reassessment.”
CPT / HCPCS:
- 67028-RT — Intravitreal injection, right eye (anti-VEGF: Eylea)
- J0178 × units per dose — Aflibercept (Eylea) (anti-VEGF — J-code for Eylea; units per administered dose)
- 92134 — OCT posterior segment (CNV confirmation, subretinal fluid measurement)
- 92235 — Fluorescein angiography (CNV characterization)
- 92014 — Comprehensive ophthalmological exam
ICD-10-CM:
- H35.3211 — Exudative age-related macular degeneration, right eye, with active choroidal neovascularization (new wet AMD conversion — primary driver for today’s anti-VEGF treatment)
- H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement (pre-existing dry AMD component remains — both conditions co-exist in the same eye)
- H54.8 — Legal blindness (if still meeting criteria — reassess with today’s VA)
Wet AMD on Top of Dry AMD — Both Codes Are Correct Simultaneously
This is one of the most nuanced dual-coding scenarios in AMD: a patient develops active CNV (wet AMD) in an eye that already has subfoveal GA (dry AMD). These are not mutually exclusive — they represent two concurrent pathologic processes in the same eye. Code both H35.3211 (wet) and H35.3114 (dry/GA) as concurrent active conditions. The wet AMD code drives the anti-VEGF treatment; the dry AMD code documents the pre-existing GA burden. Do NOT drop H35.3114 simply because wet AMD has developed — both conditions are present and clinically documented.
Scenario 4 — H35.3114 in the Inpatient Setting — Hip Fracture After Fall (Inpatient)
Clinical Vignette: An 86-year-old female with bilateral advanced AMD — right eye subfoveal GA, legal blindness right eye — is admitted for right hip fracture after a fall at home. H&P documents: “Advanced macular degeneration, right eye, with legal blindness — fell reaching for a light switch in a dim room — vision impairment contributed to fall.” Left eye: intermediate AMD.
Principal Diagnosis:
- S72.001A — Fracture of unspecified part of neck of right femur, initial encounter for closed fracture (hip fracture — principal)
Additional Diagnoses:
- H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement (documented, active, directly contributed to fall per physician)
- H54.8 — Legal blindness (established — physician documents legal blindness as contributing factor)
- H35.3122 — Nonexudative AMD, left eye, intermediate dry stage (active comorbidity)
- W19.XXXA — Unspecified fall, initial encounter (external cause — fall mechanism)
- Y93.E9 — Activity, other interior property and land maintenance (if activity documented)
"Contributed to the Fall" Language Is Your Documentation Anchor
When the physician explicitly documents that the patient’s legal blindness contributed to the fall, this language directly supports assigning H35.3114 and H54.8 as additional diagnoses that meet UHDDS criteria (“affected the treatment received and/or the length of stay”). It also creates a legally defensible clinical narrative for the admission. Encourage ophthalmology consultants and hospitalists to include this language in the H&P when vision loss is a documented fall risk factor — it transforms the AMD codes from passive comorbidities to active clinical drivers.
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never submit H35.311 (6-character) — non-billable header — H35.3114 (all 7 characters) required |
| ❌ | Never code H35.3112 or H35.3113 when subfoveal GA is documented — subfoveal GA = H35.3114; downstaging advanced AMD is the most impactful AMD coding error [web:70] |
| ❌ | Never assume GA treatment is inappropriate at H35.3114 — both Syfovre (J2781) and Izervay (J2782) are FDA-indicated regardless of subfoveal involvement; continuing GA treatment is clinically supported [web:112] |
| ❌ | Do not bill J2781 or J2782 without 67028-RT — drug code covers drug only; injection procedure is always separate |
| ❌ | Do not use wrong units — J2781 = 15 units (Syfovre 15mg); J2782 = 20 units (Izervay 2mg); unit errors cause claim denials [web:117][web:118] |
| ❌ | Do not code H35.3114 alone without assessing H54.xx — subfoveal GA almost always produces vision impairment meeting H54 criteria; omitting H54.xx is an incomplete clinical picture |
| ❌ | Do not drop H35.3114 when wet AMD (H35.3211) develops — both may co-exist in the same eye; code both as concurrent active conditions |
| ❌ | Do not use H35.3114 for wet AMD — wet AMD is always H35.32xx; H35.3114 is exclusively dry/atrophic AMD with subfoveal GA |
| ✅ | Always assess and code vision impairment (H54.xx) — legal blindness (H54.8) and laterality-specific blindness (H54.11x) are almost always applicable at H35.3114; never omit |
| ✅ | Code depression when documented — F32.9 or F33.x — up to 40% of legal blindness patients develop clinical depression; it meets UHDDS criteria when documented |
| ✅ | Document and code driving cessation — Z73.82 when physician documents driving is no longer safe; legally and clinically critical |
| ✅ | Refer and document low vision rehabilitation — referral documentation supports E/M counseling time and quality metric compliance |
| ✅ | Use bilateral code H35.3134 when both eyes have confirmed subfoveal GA; use separate laterality codes when eyes are at different stages |
| ✅ | In the inpatient setting, explicitly link legal blindness to fall causation when physician documents this relationship — it elevates H35.3114 and H54.8 from passive comorbidities to active UHDDS-qualifying additional diagnoses |
| ✅ | Track stage-upgrade documentation — when coding H35.3114 for the first time on a patient previously coded H35.3113, ensure the physician’s note explicitly confirms new subfoveal involvement; the FAF or OCT report provides objective backup |
| ✅ | Continue AREDS2 documentation — note whether patient is continuing supplementation and document clinical rationale; emerging 2025 data supports potential benefit even at advanced stages |
📚 Sources
1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2025. Tabular List — H35.311 Nonexudative AMD, 7th character staging; Excludes 2 notations; General Coding Guidelines Section I.B — Additional Diagnoses, UHDDS criteria.
2. Ferris FL, Wilkinson CP, Bird A, et al. “Clinical Classification of Age-related Macular Degeneration.” Ophthalmology. 2013;120(4):844-851. Beckman classification — advanced atrophic AMD with subfoveal involvement criteria.
3. JMCP. “Geographic atrophy and factors associated with disease progression.” January 2025. GA progression rates, epidemiology, and subfoveal involvement sequelae. [web:114]
4. Optometric Management. “Coding and Billing Updates for Geographic Atrophy Drugs.” 2025. J2781 (Syfovre, Oct 2023), J2782 (Izervay, April 2024) permanent J-code assignments; billing rules for GA treatments. [web:115]
5. Retinal Physician. “Permanent J-code for Izervay Injection.” April 2024. J2782 — 20 units per 2mg dose; billing and coding guidance. [web:120]
6. Syfovre Access Support Navigator. “Billing and Coding.” Pegcetacoplan 15 units per 15mg injection; 67028-RT required with J2781. [web:118]
7. Izervay J-Code Effective Flashcard. J2782, 20 units per 2mg dose. [web:117]
8. Louisiana Medicaid. Izervay Clinical Criteria — Medical Drug. April 2025. FDA indication scope including H35.3114; prior authorization criteria. [web:112]
9. PMC/NIH. “Variations in Using Diagnosis Codes for Defining Age-Related Macular Degeneration.” 2024. Downstaging advanced AMD as intermediate AMD — documented national undercoding pattern. [web:70]
10. FindACode. ICD-10-CM Diagnosis Code H35.3114 — Nonexudative AMD, right eye, advanced atrophic with subfoveal involvement. Confirmed billable FY2025. [web:116]
11. Unbound Medicine. H35.3114 — Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement. Code description and hierarchy. [web:113]